The Latest
-
Rebecca Pifer/PharmaVoice
How PBM reforms could push drugmakers into the pricing spotlight
The Consolidated Appropriations Act's landmark PBM overhaul removes financial incentives tied to pharma list prices, potentially leaving drugmakers to defend their own practices.
-
Getty Images
Biohaven says FDA roadblocks leave rare disease patients in limbo
An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.
-
Getty Images
China’s biopharma advance draws financial investment
Experts are still keeping a close eye on geopolitical uncertainties, but licensing deals are turning into monetary growth.
-
Getty Images
Will the FDA yank mRNA vaccines?
Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.
-
Getty Images
How does the FDA really feel about psychedelics? We could soon find out.
Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.
-
Getty Images
No one-trick pony in oncology, Merck’s cancer footprint is expanding
The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.
-
Maddie Meyer via Getty Images
Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.
Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.
-
Getty Images
AI is slashing jobs across industries. Will pharma be next?
Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive job losses for now.
-
Getty Images
Pharma could be on the cusp of finally breaking the blood-brain barrier
Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground.
-
Getty Images
More drugmakers are turning to cancer combos. Will it help patients live longer?
Researchers are increasingly trying multi-pronged approaches to stop tumors in their tracks, leaving monotherapies to the wayside.
-
Permission granted by Ovid Therapeutics
Q&A // First 90 DaysOvid takes another big swing in neuroscience under a new CEO
After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.
-
Alex Wong via Getty Images
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief
The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.
-
Scott Olson via Getty Images
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.
-
Permission granted by Omnigeniq
ProfileA protein model designed for space could expand pharma’s definition of ‘druggability’
A computational biology company that started in space tech is looking to change how biopharma finds disease targets by modeling how proteins behave.
-
Sarah Silbiger via Getty Images
New FDA guidance that’s a ‘huge deal’ for clinical trials
Why using Bayesian statistics could transform trial design for rare diseases and beyond.
-
Getty Images
In a tough market, biotechs can be their own worst enemy
Even with sound science, startups can struggle to make their candidates go the distance.
-
Getty Images
New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond
Emerging tests offer a bridge to pharma aiming to treat neurodegenerative diseases in their earlier stages.
-
Permission granted by Bayer
Bayer sets the stage for a pharma comeback
The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.
-
Kevin Dietsch via Getty Images
Big Pharma CEOs set sights on massive growth in years to come
The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.
-
Scott Olson via Getty Images
The most valuable up-and-coming GLP-1s
Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.
-
Andrew Harnik via Getty Images
Why TrumpRx is stumbling before it gets off the ground
Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.
-
Getty Images
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.
-
Permission granted by Mirum
Mirum doubles down on diversified rare disease strategy
With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.
-
Getty Images
AI regulation lags despite entering higher-risk patient care
While more pharma companies launch DTC platforms, states, not the federal government, are providing guardrails to protect patient privacy and safety.
-
Getty Images
How Big Pharma is navigating a $300 billion patent cliff
Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses.
